All Events
Canadian Science Policy Centre
1595 16th Avenue, Suite 301
Richmond Hill, ON
L4B 3N9
E-mail:
info@sciencepolicy.ca
Subscribe to the Canadian Science Policy Conference newsletter to keep up-to-date with the latest news, events and programs.
Innovation Policy encompasses all policies governing the Canadian innovation ecosystem, which includes all areas of innovation and economic development, private sector R&D, commercialization and technology policies and more. This also includes social innovation.
Science for Policy is the application and use of scientific research and knowledge to inform evidence-based decisions for public policy and regulations in all policy areas, not limited to but including public-interest policy priorities such as health, environment, national security, education, criminal justice and others.
The Policy for Science Award recognizes an individual who has pioneered policies and practices to improve the development of new technologies, capacity building and research infrastructure. Policy for Science focuses on management of science enterprises, the production of new knowledge, the development of new technology, capacity building, training highly quality personnel and research infrastructure. In general, the key targets of Policy for Science are post-secondary institutions, research funding organizations and government science-based departments and agencies.
Science Policy is inclusive of both policy for science and science for policy. Policy for Science focuses on management of science enterprises, i.e., the generation of new knowledge, the development of new technology, capacity building, training highly qualified personnel and research infrastructure. In general, the key targets of policy for science are post-secondary institutions, research funding organizations and government science-based departments and agencies. Science for policy is the application and use of scientific research and knowledge to inform evidence-based decisions for public policy and regulations in all policy areas, not limited to but including public-interest policy priorities such as health, environment, national security, education, and criminal justice and others.
Science & Society focuses on strengthening public understanding and engagement with science, including the relationship between science and society. This includes but is not limited to science communication, science journalism, public engagement, citizen scientist and more.
Dr. Graeme Moffat is a co-founder and scientist with System2 Neurotechnology. He previously was Chief Scientist and VP of Regulatory Affairs at Interaxon, Chief Scientist with ScienceScape (later Chan-Zuckerberg Meta), and a research engineer at Neurelec (a division of Oticon Medical). He served as Managing Editor of Frontiers in Neuroscience, the largest open access scholarly journal series in the field of neuroscience. Dr. Moffat is a Senior Fellow at the Munk School of Global Affairs and Public Policy and an advisor to the OECD’s neurotechnology policy initiative.
Jennifer Chandler is Professor of Law at the Centre for Health Law, Policy and Ethics, University of Ottawa. She leads the “Neuroethics Law and Society” Research Pillar for the Brain Mind Research Institute and sits on its Scientific Advisory Council. Her research focuses on the ethical, legal and policy issues in brain sciences and the law. She teaches mental health law and neuroethics, tort law, and medico-legal issues. She is a member of the advisory board for CIHR’s Institute for Neurosciences, Mental Health and Addiction (IMNA) and serves on international editorial boards in the field of law, ethics and neuroscience, including Neuroethics, the Springer Book Series Advances in Neuroethics, and the Palgrave-MacMillan Book Series Law, Neuroscience and Human Behavior. She has published widely in legal, bioethical and health sciences journals and is the co-editor of the book Law and Mind: Mental Health Law and Policy in Canada (2016). Dr. Chandler brings a unique perspective to this panel as her research focuses on the ethical, legal and policy issues at the intersection of the brain sciences and the law. She is active in Canadian neuroscience research funding policy, and regularly contributes to Canadian governmental policy on contentious matters of biomedicine.
Ian is a C5 tetraplegic from a diving accident in 2010. He participated in a ground-breaking clinical trial using a brain-computer interface to control muscle stimulation. He is the founder of the BCI Pioneers Coalition, which works to establish ethics, guidelines and best practices for future patients, clinicians, and commercial entities engaging with BCI research. Ian serves as Vice President of the North American Spinal Cord Injury Consortium and chairs their project review committee. He has also worked with Unite2Fight Paralysis to advocate for $9 million of SCI research in his home state of Ohio. Ian has been a Reeve peer mentor since 2015 and helps lead two local SCI networking groups. As the president of the Ian Burkhart Foundation, he raises funds for accessible equipment for the independence of others with SCI. Ian is also a full-time consultant working with multiple medical device companies.
Andrew Atkinson is the Manager of the Emerging Sciences Policy Unit under the Strategic Policy Branch of Health Canada. He oversees coordination of science policy issues across the various regulatory and research programs under the mandate of Health Canada. Prior to Health Canada, he was a manager under Environment Canada’s CEPA new chemicals program, where he oversaw chemical and nanomaterial risk assessments, and the development of risk assessment methodologies. In parallel to domestic work, he has been actively engaged in ISO and OECD nanotechnology efforts.
Andrew is currently a member of the Canadian delegation to the OECD Working Party on Biotechnology, Nanotechnology and Converging Technologies (BNCT). BNCT aims to contribute original policy analysis on emerging science and technologies, such as gene editing and neurotechnology, including messaging to the global community, convening key stakeholders in the field, and making ground-breaking proposals to policy makers.
Dr. Illes is Professor of Neurology and Distinguished Scholar in Neuroethics at the University of British Columbia. She is the Director of Neuroethics Canada, and among her many leadership positions in Canada, she is Vice Chair of the Canadian Institutes of Health Research (CIHR) Advisory Board of the Institute on Neuroscience, Mental Health and Addiction (INMHA), and chair of the International Brain Initiative (www.internationalbraininitiative.org; www.canadianbrain.ca), Director at Large of the Canadian Academy of Health Sciences, and a member of the Board of Directors of the Council of Canadian Academies.
Dr. Illes is a world-renown expert whose research, teaching and outreach are devoted to ethical, legal, social and policy challenges at the intersection of the brain sciences and biomedical ethics. She has made ground breaking contributions to neuroethical thinking for neuroscience discovery and clinical translation across the life span, including in entrepreneurship and in the commercialization of health care. Dr. Illes has a unique and comprehensive overview of the field of neurotechnology and the relevant sectors in Canada.